234 related articles for article (PubMed ID: 27734608)
21. Cabozantinib Exhibits Potent Antitumor Activity in Colorectal Cancer Patient-Derived Tumor Xenograft Models via Autophagy and Signaling Mechanisms.
Scott AJ; Arcaroli JJ; Bagby SM; Yahn R; Huber KM; Serkova NJ; Nguyen A; Kim J; Thorburn A; Vogel J; Quackenbush KS; Capasso A; Schreiber A; Blatchford P; Klauck PJ; Pitts TM; Eckhardt SG; Messersmith WA
Mol Cancer Ther; 2018 Oct; 17(10):2112-2122. PubMed ID: 30026382
[TBL] [Abstract][Full Text] [Related]
22. A Phase II Study of Regorafenib With a Lower Starting Dose in Patients With Metastatic Colorectal Cancer: Exposure-Toxicity Analysis of Unbound Regorafenib and Its Active Metabolites (RESET Trial).
Suzuki T; Sukawa Y; Imamura CK; Masuishi T; Satake H; Kumekawa Y; Funakoshi S; Kotaka M; Horie Y; Kawai S; Okuda H; Terazawa T; Kondoh C; Kato K; Yoshimura K; Ishikawa H; Hamamoto Y; Boku N; Takaishi H; Kanai T
Clin Colorectal Cancer; 2020 Mar; 19(1):13-21.e3. PubMed ID: 31732439
[TBL] [Abstract][Full Text] [Related]
23. Regorafenib overcomes chemotherapeutic multidrug resistance mediated by ABCB1 transporter in colorectal cancer: In vitro and in vivo study.
Wang YJ; Zhang YK; Zhang GN; Al Rihani SB; Wei MN; Gupta P; Zhang XY; Shukla S; Ambudkar SV; Kaddoumi A; Shi Z; Chen ZS
Cancer Lett; 2017 Jun; 396():145-154. PubMed ID: 28302530
[TBL] [Abstract][Full Text] [Related]
24. Regorafenib.
Ettrich TJ; Seufferlein T
Recent Results Cancer Res; 2018; 211():45-56. PubMed ID: 30069758
[TBL] [Abstract][Full Text] [Related]
25. Metabolic profiling of the anti-tumor drug regorafenib in mice.
Wang YK; Xiao XR; Xu KP; Li F
J Pharm Biomed Anal; 2018 Sep; 159():524-535. PubMed ID: 30055476
[TBL] [Abstract][Full Text] [Related]
26. Neratinib augments the lethality of [regorafenib + sildenafil].
Booth L; Roberts JL; Rais R; Cutler RE; Diala I; Lalani AS; Hancock JF; Poklepovic A; Dent P
J Cell Physiol; 2019 Apr; 234(4):4874-4887. PubMed ID: 30203445
[TBL] [Abstract][Full Text] [Related]
27. Regorafenib sensitizes human breast cancer cells to radiation by inhibiting multiple kinases and inducing DNA damage.
Mehta M; Griffith J; Panneerselvam J; Babu A; Mani J; Herman T; Ramesh R; Munshi A
Int J Radiat Biol; 2021; 97(8):1109-1120. PubMed ID: 32052681
[TBL] [Abstract][Full Text] [Related]
28. Regorafenib for treatment of advanced gastrointestinal stromal tumors.
Overton LC; Heinrich MC
Expert Opin Pharmacother; 2014 Mar; 15(4):549-58. PubMed ID: 24405315
[TBL] [Abstract][Full Text] [Related]
29. Preclinical comparison of regorafenib and sorafenib efficacy for hepatocellular carcinoma using multimodality molecular imaging.
Liu S; Du Y; Ma H; Liang Q; Zhu X; Tian J
Cancer Lett; 2019 Jul; 453():74-83. PubMed ID: 30928380
[TBL] [Abstract][Full Text] [Related]
30. The orally available multikinase inhibitor regorafenib (BAY 73-4506) in multiple myeloma.
Breitkreutz I; Podar K; Figueroa-Vazquez V; Wilhelm S; Hayden PJ; Anderson KC; Raab MS
Ann Hematol; 2018 May; 97(5):839-849. PubMed ID: 29359239
[TBL] [Abstract][Full Text] [Related]
31. A marginal anticancer effect of regorafenib on pancreatic carcinoma cells in vitro, ex vivo, and in vivo.
Mayer B; Karakhanova S; Bauer N; Liu L; Zhu Y; Philippov PP; Werner J; Bazhin AV
Naunyn Schmiedebergs Arch Pharmacol; 2017 Nov; 390(11):1125-1134. PubMed ID: 28779210
[TBL] [Abstract][Full Text] [Related]
32. Initial in vivo testing of a multitarget kinase inhibitor, regorafenib, by the Pediatric Preclinical Testing Consortium.
Harrison DJ; Gill JD; Roth ME; Zhang W; Teicher B; Erickson S; Gatto G; Kurmasheva RT; Houghton PJ; Smith MA; Kolb EA; Gorlick R
Pediatr Blood Cancer; 2020 Jun; 67(6):e28222. PubMed ID: 32207565
[TBL] [Abstract][Full Text] [Related]
33. Regorafenib: Antitumor Activity upon Mono and Combination Therapy in Preclinical Pediatric Malignancy Models.
Daudigeos-Dubus E; Le Dret L; Lanvers-Kaminsky C; Bawa O; Opolon P; Vievard A; Villa I; Pagès M; Bosq J; Vassal G; Zopf D; Geoerger B
PLoS One; 2015; 10(11):e0142612. PubMed ID: 26599335
[TBL] [Abstract][Full Text] [Related]
34. FGFR2 amplification is predictive of sensitivity to regorafenib in gastric and colorectal cancers in vitro.
Cha Y; Kim HP; Lim Y; Han SW; Song SH; Kim TY
Mol Oncol; 2018 Jun; 12(7):993-1003. PubMed ID: 29573334
[TBL] [Abstract][Full Text] [Related]
35. Lack of Contribution of Multidrug Resistance-associated Protein and Organic Anion-transporting Polypeptide to Pharmacokinetics of Regorafenib, a Novel Multi-Kinase Inhibitor, in Rats.
Hotta K; Ueyama J; Tatsumi Y; Tsukiyama I; Sugiura Y; Saito H; Matsuura K; Hasegawa T
Anticancer Res; 2015 Sep; 35(9):4681-9. PubMed ID: 26254357
[TBL] [Abstract][Full Text] [Related]
36. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
37. Disrupting VEGF-A paracrine and autocrine loops by targeting SHP-1 suppresses triple negative breast cancer metastasis.
Su JC; Mar AC; Wu SH; Tai WT; Chu PY; Wu CY; Tseng LM; Lee TC; Chen KF; Liu CY; Chiu HC; Shiau CW
Sci Rep; 2016 Jul; 6():28888. PubMed ID: 27364975
[TBL] [Abstract][Full Text] [Related]
38. Multikinase-Inhibitor Screening in Drug-resistant Osteosarcoma Patient-derived Orthotopic Xenograft Mouse Models Identifies the Clinical Potential of Regorafenib.
Higuchi T; Igarashi K; Yamamoto N; Hayashi K; Kimura H; Miwa S; Bouvet M; Tsuchiya H; Hoffman RM
Cancer Genomics Proteomics; 2021; 18(5):637-643. PubMed ID: 34479916
[TBL] [Abstract][Full Text] [Related]
39. Resistance to multikinase inhibitor actions mediated by insulin like growth factor-1.
Lippolis C; Refolo MG; D'Alessandro R; Carella N; Messa C; Cavallini A; Carr BI
J Exp Clin Cancer Res; 2015 Sep; 34(1):90. PubMed ID: 26329608
[TBL] [Abstract][Full Text] [Related]
40. The effect of gastrectomy on regorafenib exposure and progression-free survival in patients with advanced gastrointestinal stromal tumours.
Lubberman FJE; van der Graaf WTA; Xu L; Cleton A; Demetri GD; Gelderblom H; van Erp NP
Br J Clin Pharmacol; 2019 Oct; 85(10):2399-2404. PubMed ID: 31290566
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
